Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 1997

Conditions
Head and Neck Cancer
Interventions
DRUG

paclitaxel

Trial Locations (20)

10011

Saint Vincent Catholic Medical Center of New York, New York

13905

Lourdes Regional Cancer Center, Binghamton

24541

Danville Hematology and Oncology, Inc., Danville

31405

Savannah Hematology Oncology Associates, Savannah

33021

Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood

33136

Sylvester Cancer Center, University of Miami, Miami

44309

Akron City Hospital, Akron

45409

Medical Oncology Hematology Associates, Inc., Dayton

53226

Medical College of Wisconsin, Milwaukee

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

64132

Kansas City Internal Medicine, Kansas City

70809

Mary Bird Perkins Cancer Center, Baton Rouge

78229

Cancer Care Institute of South Texas, San Antonio

92354

Loma Linda University Medical Center, Loma Linda

93720

California Cancer Center, Fresno

04074

Maine Center for Cancer Medicine and Blood Disorders, Scarborough

21231-2410

Johns Hopkins Oncology Center, Baltimore

28233-3549

Presbyterian Healthcare, Charlotte

19612-6052

Reading Hospital and Medical Center, Reading

79410-1894

Joe Arrington Cancer Research and Treatment Center, Lubbock

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theradex

INDUSTRY